FibroBiologics, Inc.
FBLG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001958777
No open-market purchases or sales by FibroBiologics, Inc. insiders were filed in the last 90 days; 16 institutions reported holding it in 13F filings for Q2 2026, worth $269.6K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding FibroBiologics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 17 | 16 | −1 |
| Shares | 220.7K | 284.9K | +64.3K (+29.1%) |
| Value | $291.1K | $269.6K | −$21.4K (−7.4%) |
New holders (3)
Institutions that held FibroBiologics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 24,313 | $23.0K | 0.00% |
| Barclays PLC | 7,243 | $6.86K | 0.00% |
| Grove Bank & Trust | 100 | $95 | 0.00% |
Sold out (4)
Institutions that held FibroBiologics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Renaissance Technologies LLC | 15,997 | $21.1K |
| GWM Advisors LLC | 845 | $1.11K |
| Vanguard Global Advisers, LLC | 536 | $708 |
| Wells Fargo & Company | 10 | $13 |